23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

23andMe reports strong Q1 growth, focuses on profitability and partnerships

23andMe demonstrated strong growth in customer base and subscription members, with a focus on margin expansion and revenue growth. The company faces challenges in achieving profitability but has opportunities to leverage genetics for healthcare transformation and pursue partnerships. Overall, 23andMe's performance reflects a strategic focus on growth and financial discipline.

23andMe reports Q1 revenue decline, focuses on therapeutics and AI

Despite a decrease in Q1 2023 revenue, 23andMe demonstrated strength in its therapeutics business and strategic pricing initiatives. The company faces challenges with significant workforce reduction and higher operating expenses but has opportunities in advancing immuno-oncology assets and leveraging AI advancements.

23andMe reports revenue growth and strategic initiatives for future expansion

Overall, 23andMe's Q3 performance showcased growth and innovation in both consumer and therapeutic segments. While facing challenges with increased expenses and a net loss, the company's raised full-year guidance and strategic initiatives present opportunities for future expansion and profitability.

23andMe reports revenue growth and strategic healthcare integration plans

23andMe's Q4 2023 earnings call showcased strong revenue growth, new health report offerings, and advancements in therapeutics. Despite financial projections indicating a net loss and EBITDA deficit for FY 2024, the company remains focused on expanding margins and capital efficiency. Integration of telehealth services and personalized care present promising opportunities for future growth.

23andMe reports Q1 revenue decline, eyes growth in therapeutics

23andMe navigated challenges with workforce reductions and revenue decline, focusing on margin improvement and cost discipline. The company aims to capitalize on opportunities in therapeutics and consumer businesses through strategic initiatives. With a strong cash position and guidance for improvement in adjusted EBITDA deficit, 23andMe is positioning for future growth.

23andMe reports Q2 revenue of $50M, focuses on margin expansion

23andMe's Q2 2024 performance showed revenue of $50 million with a net loss of $75 million, emphasizing margin expansion.
Strengths include new subscription offerings, FDA clearances, promising therapeutics pipeline, and data security focus.
Challenges include net losses, adjusted EBITDA deficit, and updated FY 2024 guidance reflecting uncertainties.
Opportunities lie in expanding subscription services, enhancing product offerings, and leveraging collaborations for growth.

23andMe reports Q3 revenue decline, focuses on strategic growth

23andMe faced revenue decline and increased expenses, leading to a significant net loss and revised guidance for fiscal year 2024.
Despite challenges, the company showcased strengths in strategic progress, therapeutics advancements, and extended collaborations.
Opportunities lie in margin expansion, cash flow profitability, and leveraging consumer offerings and partnerships for future growth.

23andMe reports strong revenue growth and strategic shifts for growth

23andMe showcased strong performance in membership revenue growth and advancements in research and therapeutics, despite challenges in revenue and operating expenses.
The company's strategic shift towards high-value programs and partnerships with GSK position it well for long-term growth and innovation in the genetic testing and healthcare space.
While facing challenges in cost management and revenue generation, 23andMe has opportunities to optimize operations, drive growth through new programs, and address compliance issues.
Overall, 23andMe's focus on innovation, strategic collaborations, and operational efficiency sets the stage for navigating challenges and capitalizing on growth opportunities in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

23andMe Holding Co. is gearing up to capitalize on its growing genetic database by investing in new business verticals and industry-first services.

23andMe: A Genetics Innovator Positioned For Growth

SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Citi 2022 Virtual Healthcare Conference on February 24, 2022 at 1:15 pm Eastern Time.

23andMe to Present at Citi's 2022 Virtual Healthcare Conference

It depends on whether you look at where the company is today or where it's going tomorrow.

After Falling 67% in 1 Year, Is 23andMe Undervalued?

It's positioned to capitalize on the data from its consumer genetics business.

4 Green Flags for 23andMe's Future

Arrival Group

Bloom Energy

Fiverr

Lemonade

Skillz

Stem, Inc

Although the market is full of potential pitfalls, risk-tolerant contrarians could consider these discounted stocks to buy. The post 7 Badly Bruised Stocks to Buy for the Tough-as-Nails Contrarian appeared first on InvestorPlace.

7 Badly Bruised Stocks to Buy for the Tough-as-Nails Contrarian

23andMe Holding Co. (ME) CEO Anne Wojcicki on Q3 2022 Results - Earnings Call Transcript

Third quarter revenue of $57 million  Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials  Vision of genetics-based primary care offers potential for millions of people to live healthier lives

23andMe Reports FY2022 Third Quarter Financial Results

Fulgent Genetics

UnitedHealth Group

There are a few different ways to invest in this sector, but will it be a winner in 2022?

This Sector is 13% of the Stock Market and Has Lifelong Potential

Clear Channel Outdoor Holdings

Esports Entertainment Group

Mesa Air Group Inc.

Marin Software

Pangaea Logistics Solutions

Exela Technologies

Penny stocks can rise quickly on relatively small catalysts, making them a great gamble. Here are a few that should rise.

7 Penny Stocks With the Biggest Chance of Blasting Off This Year

SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) third quarter after the market closes on Thursday, February 10, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter's financial results and report on business progress.

23andMe to Report FY2022 Third Quarter Financial Results

The Beachbody Co.

Buzzfeed

Hims & Hers Health

Stryve Foods

Are these household stocks under $5 on your watch list in 2022? The post 10 Top Penny Stocks To Buy Under $5 That Are Household Names appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy Under $5 That Are Household Names

Genetic testing company 23andMe now has another thing in common with many Disruptor 50 companies – it has to convince investors to believe in the next act.

One of Google's earliest genetic experiments, 23andMe, paid off — here's what will make or break its future

Genetic testing company 23andMe Holding Co. (NASDAQ: ME) took the unconventional route of a SPAC deal to go public, and the stock hasn't gained much traction since it began trading on June 17, 2021. The new year saw the company announcing its diversification into drug development.

23andMe Pivoting To Clinical Research: Could That Lead To A Turnaround For The Stock?

GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using  23andMe's proprietary genetic and health survey database

23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program

The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutation

23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker

23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells

23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors

SUNNYVALE, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the results of the completed redemption (the “Redemption”) of all of its outstanding warrants (the “Warrants”) to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dated October 1, 2020 (the “Warrant Agreement”), by and between 23andMe and Continental Stock Transfer & Trust Company, as warrant agent. The Warrants include the public warrants (the “Public Warrants”) issued as part of the units sold in the initial public offering (the “IPO”) of 23andMe, which was formerly known as VG Acquisition Corp., and the private warrants that were sold in a private placement simultaneously with the IPO.

23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants

Medpace Holdings

Mesa Laboratories

These smaller healthcare companies all have 10x potential for investors.

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

GlaxoSmithKline

These two companies have massive growth opportunities and have declined sharply in recent months.

2 Cheap Stocks With 10X Potential to Buy in 2022

Airbnb

Legalzoom.com

3 Top IPO Stocks to Put on Your Watchlist

Poshmark

Riskified Ltd

With these kinds of resources, these companies are becoming less-risky investments.

Like Strong Balance Sheets? These 3 Stocks Are Loaded With Cash

The company reported disappointing earnings results and has fallen victim to the recent sell-off in high-growth stocks.

Why 23andMe Stock Dropped 29% in November

Her genetics testing company is the latest to flounder after going public via SPAC.

Anne Wojcicki's 23andMe Fortune Falls Under $1 Billion As Shares Sink Post-IPO

Dr. Arron brings nearly two decades of scientific leadership in biotech drug discovery and development to 23andMe's Therapeutics team Dr. Arron brings nearly two decades of scientific leadership in biotech drug discovery and development to 23andMe's Therapeutics team

23andMe Announces the Appointment of Joseph R. Arron, M.D.

SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dated October 1, 2020 (the “Warrant Agreement”), by and between 23andMe and Continental Stock Transfer & Trust Company, as warrant agent (the “Warrant Agent”), as part of the units sold in the initial public offering (the “IPO”) of 23andMe, which was formerly known as VG Acquisition Corp., and that remain outstanding at 5:00 p.m. New York City time on December 22, 2021 (the “Redemption Date”) for a redemption price of $0.10 per Public Warrant. In addition, 23andMe will redeem all of its outstanding warrants to purchase Class A common stock that were issued under the Warrant Agreement in a private placement simultaneously with the IPO (the “Private Warrants” and, together with the Public Warrants, the “Warrants”) on the same terms as the outstanding Public Warrants.

News for 23andMe Stock (ME)